Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC)

被引：0

作者：

Kabaker, K. B.

Canar, J.

Rao, R. D.

Cobleigh, M. A.

机构：

[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[2] Edward Hines Jr VA Hosp, Hines, IL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.620

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

620

引用

页数：1

共 50 条

[1] Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC)
Lau, A.
Miller, D.
Davison, D.
Rothney, M.
Borgen, P.
BREAST, 2017, 32 : S97 - S97
[2] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
Meisel, Jane
Zhang, Chao
Neely, Cameron
Menduza, Pia
You, Shuo
Han, Tatiana
Liu, Yuan
Sahin, Aysegul A.
O'Regan, Ruth
Li, Xiaoxian
CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
[3] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
Logan, Suzanna J.
Zhang, Chao
Liu, Yuan
Siddiqui, Momin T.
Cohen, Cynthia
Li, Xiaoxian
MODERN PATHOLOGY, 2017, 30 : 56A - 57A
[4] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
Logan, Suzanna J.
Zhang, Chao
Liu, Yuan
Siddiqui, Momin T.
Cohen, Cynthia
Li, Xiaoxian
LABORATORY INVESTIGATION, 2017, 97 : 56A - 57A
[5] Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
Browne, Iseult
McLaughlin, Ronan
Weadick, Catherine
O'Sullivan, Shane
Millen, Steve
Hadi, Danial
Bilal-Shah, Syed
Al Sendhi, Maha
Higgins, Michaela
Crown, John
Prichard, Ruth
McCartan, Damian
Hill, Arnold
Connolly, Roisin
Noonan, Sinead
O'Mahony, Deirdre
O'Hanlon-Brown, Ciara
Hennessy, Bryan
Quinn, Cecily
Kelly, Catherine M.
O'Reilly, Seamus
Morris, Patrick G.
Walshe, Janice
CANCER RESEARCH, 2024, 84 (09)
[6] A retrospective study of 21-gene recurrence score assay compared with clinicopathological markers in node-negative, hormone receptor-positive, HER2-negative breast cancer.
Chen, Junqing
Wang, Xiaojia
Chen, Zhanhong
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Ditsch, Nina
Schmidt, Marcus
GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
[8] Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer
Pusztai, Lajos
Hoag, Jess R.
Albain, Kathy S.
Barlow, William E.
Stemmer, Salomon M.
Meisner, Allison
Hortobagyi, Gabriel N.
Shak, Steven
Hayes, Daniel F.
Rae, James M.
Baehner, Frederick
Sharma, Priyanka
Kalinsky, Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
Weiser, Roi
Haque, Waqar
Polychronopoulou, Efstathia
Hatch, Sandra S.
Kuo, Yong-fang
Gradishar, William J.
Klimberg, V. Suzanne
BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 667 - 676
[10] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
Roi Weiser
Waqar Haque
Efstathia Polychronopoulou
Sandra S. Hatch
Yong-fang Kuo
William J. Gradishar
V. Suzanne Klimberg
Breast Cancer Research and Treatment, 2021, 185 : 667 - 676

← 1 2 3 4 5 →